, Tracking Stock Market Picks
Enter Symbol:
Anacor Pharmaceuticals Inc (ANAC) [hlAlert]

down 10.02 %

Anacor Pharmaceuticals Inc (ANAC) rated Buy by BofA/Merrill

Posted on: Tuesday,  Jul 21, 2015  10:25 AM ET by BofA/Merrill

BofA/Merrill rated Buy Anacor Pharmaceuticals Inc (NASDAQ: ANAC) on 07/21/2015, when the stock price was $148.50. Since
then, Anacor Pharmaceuticals Inc has lost 10.02% as of 01/26/2016's recent price of $133.62.
If you would have followed this BofA/Merrill's recommendation on ANAC, you would have lost 10.02% of your investment in 189 days.

Anacor Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing small-molecule therapeutics derived from its boron chemistry platform. The Company has five product candidates in clinical development. Its three product candidates include two topically administered dermatologic compounds: AN2690, an antifungal for the treatment of onychomycosis, and AN2728, an anti-inflammatory for the treatment of psoriasis, as well as a systemic antibiotic for the treatment of infections caused by Gram-negative bacteria GSK2251052 (GSK '052). The Company is developing AN2718 as a topical antifungal product candidate for the treatment of onychomycosis and skin fungal infections, and AN2898 as a topical anti-inflammatory product candidate for the treatment of psoriasis and atopic dermatitis. In August 2010, it entered into a research agreement with Eli Lilly and Company (Lilly).

Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/21/2015 10:25 AM Buy
as of 8/27/2015
1 Week down  -5.72 %
1 Month up  74.50 %
3 Months down  -10.02 %
1 YTD down  -10.02 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy